Chloroaluminium sulphonate phthalocyanine
Alternative Names: Chloroaluminum sulfonated phthalocyanineLatest Information Update: 23 Nov 2001
At a glance
- Originator Novartis
- Class Antineoplastics; Phthalocyanines
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 23 Nov 2001 Profile reviewed but no significant changes made
- 28 Oct 1997 No-Development-Reported for Bladder cancer in Switzerland (Unknown route)
- 06 Oct 1995 Chloroaluminum sulfonated phthalocyanine is now called chloroaluminium sulphonate phthalocyanine